PDCD1 and cancer: Supported by the appearance of immunological cutaneous adverse events such as LP and lichenoid eruption after using PD-1 inhibitors in the treatment of cancers [14], all these findings call for a deeper investigation of the role of PD-1/PD-L1 levels in LP pathogenesis.